|Articles|February 1, 2004

Phase III under way

New York - Adjuvant therapy with a macrophage-activating growth factor appears to prolong survival in high-risk melanoma, Lynn E. Spitler, M.D., said.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME